Cargando…
HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine
The vaccines designed against the SARS-CoV-2 coronavirus are based on the spike (S) protein. Processing of the S protein by antigen-presenting cells (APC) and its subsequent presentation to T cells is an essential part of the development of a humoral response. HLA-class II alleles are considered imm...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949280/ https://www.ncbi.nlm.nih.gov/pubmed/35335034 http://dx.doi.org/10.3390/vaccines10030402 |
_version_ | 1784674857532784640 |
---|---|
author | Gutiérrez-Bautista, Juan Francisco Sampedro, Antonio Gómez-Vicente, Esther Rodríguez-Granger, Javier Reguera, Juan Antonio Cobo, Fernando Ruiz-Cabello, Francisco López-Nevot, Miguel Ángel |
author_facet | Gutiérrez-Bautista, Juan Francisco Sampedro, Antonio Gómez-Vicente, Esther Rodríguez-Granger, Javier Reguera, Juan Antonio Cobo, Fernando Ruiz-Cabello, Francisco López-Nevot, Miguel Ángel |
author_sort | Gutiérrez-Bautista, Juan Francisco |
collection | PubMed |
description | The vaccines designed against the SARS-CoV-2 coronavirus are based on the spike (S) protein. Processing of the S protein by antigen-presenting cells (APC) and its subsequent presentation to T cells is an essential part of the development of a humoral response. HLA-class II alleles are considered immune response genes because their codified molecules, expressed on the surface of APCs (macrophages, dendritic, and B cells) present antigenic peptides to T cell via their T cell receptor (TCR). The HLA-class II genes are highly polymorphic, regulating what specific peptides induce follicular helper T cells (TFH) and promote B lymphocyte differentiation into plasma or memory B cells. This work hypothesizes that the presence of certain HLA-class II alleles could be associated with the intensity of the humoral response (amount, length) to the SARS-CoV2 mRNA 1273 vaccine. We have studied the relationship between the HLA-class II typing of 87 health workers and the level of antibodies produced 30 days after vaccination. We show a possible association between the HLA-DRB1* 07:01 allele and the HLA-DRB1*07:01~DQA1*02:01~DQB1*02:02 haplotype to a higher production of antibodies 30 days after the administration of the second dose of mRNA-1273. |
format | Online Article Text |
id | pubmed-8949280 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89492802022-03-26 HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine Gutiérrez-Bautista, Juan Francisco Sampedro, Antonio Gómez-Vicente, Esther Rodríguez-Granger, Javier Reguera, Juan Antonio Cobo, Fernando Ruiz-Cabello, Francisco López-Nevot, Miguel Ángel Vaccines (Basel) Article The vaccines designed against the SARS-CoV-2 coronavirus are based on the spike (S) protein. Processing of the S protein by antigen-presenting cells (APC) and its subsequent presentation to T cells is an essential part of the development of a humoral response. HLA-class II alleles are considered immune response genes because their codified molecules, expressed on the surface of APCs (macrophages, dendritic, and B cells) present antigenic peptides to T cell via their T cell receptor (TCR). The HLA-class II genes are highly polymorphic, regulating what specific peptides induce follicular helper T cells (TFH) and promote B lymphocyte differentiation into plasma or memory B cells. This work hypothesizes that the presence of certain HLA-class II alleles could be associated with the intensity of the humoral response (amount, length) to the SARS-CoV2 mRNA 1273 vaccine. We have studied the relationship between the HLA-class II typing of 87 health workers and the level of antibodies produced 30 days after vaccination. We show a possible association between the HLA-DRB1* 07:01 allele and the HLA-DRB1*07:01~DQA1*02:01~DQB1*02:02 haplotype to a higher production of antibodies 30 days after the administration of the second dose of mRNA-1273. MDPI 2022-03-06 /pmc/articles/PMC8949280/ /pubmed/35335034 http://dx.doi.org/10.3390/vaccines10030402 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gutiérrez-Bautista, Juan Francisco Sampedro, Antonio Gómez-Vicente, Esther Rodríguez-Granger, Javier Reguera, Juan Antonio Cobo, Fernando Ruiz-Cabello, Francisco López-Nevot, Miguel Ángel HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine |
title | HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine |
title_full | HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine |
title_fullStr | HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine |
title_full_unstemmed | HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine |
title_short | HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine |
title_sort | hla class ii polymorphism and humoral immunity induced by the sars-cov-2 mrna-1273 vaccine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949280/ https://www.ncbi.nlm.nih.gov/pubmed/35335034 http://dx.doi.org/10.3390/vaccines10030402 |
work_keys_str_mv | AT gutierrezbautistajuanfrancisco hlaclassiipolymorphismandhumoralimmunityinducedbythesarscov2mrna1273vaccine AT sampedroantonio hlaclassiipolymorphismandhumoralimmunityinducedbythesarscov2mrna1273vaccine AT gomezvicenteesther hlaclassiipolymorphismandhumoralimmunityinducedbythesarscov2mrna1273vaccine AT rodriguezgrangerjavier hlaclassiipolymorphismandhumoralimmunityinducedbythesarscov2mrna1273vaccine AT reguerajuanantonio hlaclassiipolymorphismandhumoralimmunityinducedbythesarscov2mrna1273vaccine AT cobofernando hlaclassiipolymorphismandhumoralimmunityinducedbythesarscov2mrna1273vaccine AT ruizcabellofrancisco hlaclassiipolymorphismandhumoralimmunityinducedbythesarscov2mrna1273vaccine AT lopeznevotmiguelangel hlaclassiipolymorphismandhumoralimmunityinducedbythesarscov2mrna1273vaccine |